• Citer

Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis

par Pizzamiglio, Sara;Ciniselli, Chiara Maura;Triulzi, Tiziana;Gargiuli, Chiara;Cecco, Loris De;de Azambuja, Evandro ;Fumagalli, Debora ;Sotiriou, Christos ;Harbeck, Nadia;Izquierdo, Miguel;Nuciforo, Paolo Giovanni;Huober, J.;Cappelletti, Vera;Cinieri, Saverio;Piccart-Gebhart, Martine ;Daidone, Maria Grazia;Pruneri, Giancarlo;Colombo, Mario Paolo;Tagliabue, Elda;Verderio, Paolo;Cosimo, Serena Di
Référence Clinical cancer research, 27, 23, page (6307-6313)
Publication Publié, 2021-12-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Auteur:	Pizzamiglio, Sara; Ciniselli, Chiara Maura; Triulzi, Tiziana; Gargiuli, Chiara; Cecco, Loris De; de Azambuja, Evandro; Fumagalli, Debora; Sotiriou, Christos; Harbeck, Nadia; Izquierdo, Miguel; Nuciforo, Paolo Giovanni; Huober, J.; Cappelletti, Vera; Cinieri, Saverio; Piccart-Gebhart, Martine; Daidone, Maria Grazia; Pruneri, Giancarlo; Colombo, Mario Paolo; Tagliabue, Elda; Verderio, Paolo; Cosimo, Serena Di
Informations sur la publication:	Clinical cancer research, 27, 23, page (6307-6313)
Statut de publication:	Publié, 2021-12-01
Sujet CREF:	Cancérologie
MeSH keywords:	Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
	Breast Neoplasms -- drug therapy -- genetics -- pathology
	Female
	Humans
	Neoadjuvant Therapy
	Neoplasm Recurrence, Local -- drug therapy
	Phenotype
	Receptor, ErbB-2 -- genetics -- therapeutic use
	Trastuzumab -- therapeutic use
	Treatment Outcome
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1078-0432
	info:doi/10.1158/1078-0432.CCR-21-1600
	info:pii/1078-0432.CCR-21-1600
	info:scp/85120475656
	info:pmid/34548320